Introduction: Device-detected subclinical atrial fibrillation (AF) is common in patients with implanted cardiac rhythm devices. The ARTESiA trial demonstrated that in patients with subclinical AF, apixaban, as compared to aspirin, reduced stroke (0.98% versus 2.25% per year, 5 fewer strokes in 4 years with CHA 2 DS 2 -VASc > 4). However, apixaban also increased major bleeding (2.13% vs 1.45% per year, 2.72 more bleeds in 4 years with CHA 2 DS 2 -VASc > 4). Our objective was to estimate patient thresholds for stroke prevention and bleeding avoidance, as these factors may influence treatment decisions. Methods: Trained interviewers enrolled patients with a CHA 2 DS 2 -VASc score ≥ 4 (irrespective of AF history) from a tertiary care pacemaker/defibrillator clinic. Participants underwent a structured interview with a probability trade-off tool. We determined risk thresholds for the minimum 4-year reduction in stroke necessary to prefer apixaban compared to aspirin (minimal important difference, stroke MID) and the maximum tolerable number of major bleeds to prevent one stroke (maximum allowable difference, bleed MAD). We grouped participants into one of four preference clusters: stroke averse (accepting of bleeds to prevent stroke), bleeding averse (accepting of stroke to prevent bleeds), realist (accepting of stroke or bleed) and idealist (unwilling to accept stroke or bleed). Results: Among 415 individuals approached, 300 participants consented and 275 completed the full interview. Mean age was 81.5 ± 6.9 years, 55.3% were female, median CHA 2 DS 2 -VASc score was 4 (IQR 4-5), and 148 (53.8%) had a history of AF. The overall mean stroke MID was 5.0 ± 4.5, meaning that on average, patients require a 5% reduction in stroke over 4 years of follow up to justify apixaban over aspirin. The overall bleed MAD was 8.0 ± 4.0, meaning that on average, patients were willing to endure 8 additional major bleeds to prevent one stroke. The highest proportion of participants were stroke averse (49.1%); a minority were bleeding averse (16.7%), realist (15.3%) and idealist (18.9%) [Figure]. Conclusions: Among patients with a cardiac rhythm device and CHA 2 DS 2 -VASc ≥ 4, the mean stroke risk reduction to justify the increased bleeding risk on apixaban, as compared to aspirin, is in line with the reduction in stroke seen for patients with subclinical AF in ARTESiA. Patients will accept a mean 8 additional bleeds to prevent one stroke. Patients are 3 times more likely to be stroke averse than bleeding averse.